NASDAQ
Genetic Technologies Limited (GENE) has a price/sales ratio of 1.27x as of Friday, May 22, 2026. This represents a 99.27% decrease compared to its 12-month average of 175.57x. The price-to-sales ratio evaluates a company's stock price relative to its revenue, useful for valuing companies with little or no earnings.
No price data available for this timeframe.